Aqua Bio Technology ASA - Primary Insider Notifications

09 Apr 2025 15:32 CEST

9.4.2025 15:32:18 CEST | Aqua Bio Technology ASA | Mandatory notification of
trade primary insiders

Reference is made to the stock exchange notices from Aqua Bio Technology ASA ("
ABT" or the "Company") published on 11 March 2025 regarding the successful
placement of a private placement of 48,432,000 new shares (the "New Shares") in
the Company, at a fixed subscription price of NOK 0.50 per New Share (the "
Private Placement").

In an extraordinary general meeting held on 9 April 2025, the share capital
increase in connection with the issuance of the New Shares was approved.
Completion of the Private Placement by issuance of the New Shares remains
subject to, inter alia, valid subscription and settlement of share deposits for
all New Shares as well as completion of a share capital decrease resolved in the
extraordinary general meeting held on 9 April 2025.



The following primary insiders or close associates of primary insiders have been
allocated New Shares:



* Initia AB, a company closely associated with former director Jan Pettersson,
has been allocated 500,000 New Shares, for a total subscription amount of NOK
250,000;
* Swelandia International AB, a company closely associated with former director
Jan Pettersson, has been allocated 500,000 New Shares, for a total
subscription amount of NOK 250,000;
* Jan Pettersson, former director, has been allocated 760,000 New Shares, for a
total subscription amount of NOK 380,000;
* Roger Sedal, newly elected Chairman, has been allocated 3,324,320 New Shares,
for a total subscription amount of NOK 1,662,160;
* Terabyte Holding AS, a company closely associated with director Terje Blytt,
has been allocated 4,621,620 New Shares, for a total subscription amount of
NOK 2,310,810; and
* Varming Holding AS, a company closely associated with director Lena Varming,
has been allocated 4,000,000 New Shares, for a total subscription amount of
NOK 2,000,000.



Please see the attached notification forms for further information.



* * *



For further information, please contact Fredrik Henriksen, CEO, telephone +47
900 20 078.



Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skincare products. ABT's cosmetics ingredients are
highly effective, and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skincare products developed by partners towards consumers and
professional users. ABT's focus on commercialization and development of natural
ingredients and natural skincare products has been, and will continue to be, an
important part of the Company's strategy going forward. ABT is listed on the
Euronext Expand market of the Oslo Stock Exchange.



* * *



This information is subject to the disclosure requirements pursuant to MAR
article 19 and section 5-12 of the Norwegian Securities Trading Act.



The stock exchange announcement was published by Jan Varming on the time and
date provided.



DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Fredrik Henriksen, CEO, Aqua Bio Technology ASA, +47 90 02 00 78,
fredrik.henriksen@aquabiotech.no

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology ASA (ABT) is a distribution group in skincare and nonfood.
The group has distribution towards B2C, B2B, B2B2, and freight, customs, and
logistics services. The group also develops sustainable biotechnology for use in
skincare products. Aqua Bio Technology is listed on the Euronext Expand market
of the Oslo Stock Exchange.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18491094/5932/Download%20announce
ment%20as%20PDF.pdf

Notification form.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18491094/5931/Notification%20form
.pdf

More information:
Access the news on Oslo Bors NewsWeb site

643321_Download announcement as PDF.pdf
643321_Notification form.pdf